These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36309761)

  • 1. Medical cannabis, CBD wellness products and public awareness of evolving regulations in the United Kingdom.
    Erridge S; Coomber R; Sodergren MH
    J Cannabis Res; 2022 Oct; 4(1):56. PubMed ID: 36309761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usage and health perception of cannabidiol-containing products among the population in Germany: a descriptive study conducted in 2020 and 2021.
    Geppert J; Lietzow J; Hessel-Pras S; Kirsch F; Schäfer B; Sachse B
    BMC Public Health; 2023 Nov; 23(1):2318. PubMed ID: 37996800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Awareness of medical cannabis regulations among UK police officers - a cross-sectional study.
    Erridge S; Wang C; Troup L; Sodergren MH
    Med Leg J; 2024 Jun; 92(2):99-102. PubMed ID: 38757607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homegrown perceptions about the medical use and potential abuse of CBD and THC.
    McFadden BR; Malone T
    Addict Behav; 2021 Apr; 115():106799. PubMed ID: 33387977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on formation of medical cannabis market in Ukraine based on holistic approach.
    Aliekperova N; Kosyachenko К; Kaniura O
    J Cannabis Res; 2020 Oct; 2(1):33. PubMed ID: 33526139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to cannabidiol without a prescription: A cross-country comparison and analysis.
    McGregor IS; Cairns EA; Abelev S; Cohen R; Henderson M; Couch D; Arnold JC; Gauld N
    Int J Drug Policy; 2020 Nov; 85():102935. PubMed ID: 32919298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and Perceptions of Cannabidiol Products in Canada and in the United States.
    Goodman S; Wadsworth E; Schauer G; Hammond D
    Cannabis Cannabinoid Res; 2022 Jun; 7(3):355-364. PubMed ID: 33998872
    [No Abstract]   [Full Text] [Related]  

  • 8. Source of cannabinoids: what is available, what is used, and where does it come from?
    Specchio N; Pietrafusa N; Cross HJ
    Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recreational Cannabidiol: Awareness, Prevalence of use, and Associated Factors in a Representative Sample of the German Population.
    Alayli AFG; Kotz D; Kastaun S
    Subst Use Misuse; 2022; 57(9):1417-1424. PubMed ID: 35686726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabidiol use and perceptions in France: a national survey.
    Casanova C; Ramier C; Fortin D; Carrieri P; Mancini J; Barré T
    BMC Public Health; 2022 Aug; 22(1):1628. PubMed ID: 36038869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers.
    Zenone MA; Snyder J; Crooks V
    BMC Public Health; 2021 Jul; 21(1):1285. PubMed ID: 34210299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over the counter low-dose cannabidiol: A viewpoint from the ACRE Capacity Building Group.
    Hallinan CM; Eden E; Graham M; Greenwood LM; Mills J; Popat A; Truong L; Bonomo Y
    J Psychopharmacol; 2022 Jun; 36(6):661-665. PubMed ID: 34344208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory Status of Cannabidiol in the United States: A Perspective.
    Corroon J; Kight R
    Cannabis Cannabinoid Res; 2018; 3(1):190-194. PubMed ID: 30283822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot.
    Pennypacker SD; Cunnane K; Cash MC; Romero-Sandoval EA
    Front Pharmacol; 2022; 13():921493. PubMed ID: 35734402
    [No Abstract]   [Full Text] [Related]  

  • 15. Cannabidiol and Other Cannabinoids: From Toxicology and Pharmacology to the Development of a Regulatory Pathway.
    Koturbash I; MacKay D
    J Diet Suppl; 2020; 17(5):487-492. PubMed ID: 32715797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol usage, efficacy, and side effects: analyzing the impact of health conditions, medications, and cannabis use in a cross-sectional online pilot study.
    Binkowska AA; Jakubowska N; Redeł A; Laskowska S; Szlufik S; Brzezicka A
    Front Psychiatry; 2024; 15():1356009. PubMed ID: 38487574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabis use in Europe: Current trends and public health concerns.
    Manthey J
    Int J Drug Policy; 2019 Jun; 68():93-96. PubMed ID: 31030057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
    Mead A
    Epilepsy Behav; 2017 May; 70(Pt B):288-291. PubMed ID: 28169144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabidiol - therapeutic and legal aspects.
    Vlad RA; Hancu G; Ciurba A; Antonoaea P; Rédai EM; Todoran N; Silasi O; Muntean DL
    Pharmazie; 2020 Oct; 75(10):463-469. PubMed ID: 33305718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.